Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ono Pharmaceutical CoFRA:ON4 +0.23%87 Return-on-Tangible-Equity is 0.71% as of Mar. 2026, which is 95% below its 10-year median of 13.11. GuruFocus rates FRA:ON4 with a GF Score™ of 87/100 and a GF Value™ of €12.10 (Fairly Valued). The stock has 4 warning signs investors should review. Among 901 Drug Manufacturers companies, Ono Pharmaceutical Co ranks better than 72.25% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Ono Pharmaceutical Co's annualized net income for the quarter that ended in Mar. 2026 was €18 Mil. Ono Pharmaceutical Co's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €2,521 Mil. Therefore, Ono Pharmaceutical Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 0.71%.
The historical rank and industry rank for Ono Pharmaceutical Co's Return-on-Tangible-Equity or its related term are showing as below:
FRA:ON4'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 8.58 Med: 13.11 Max: 18.17
Current: 16.08
During the past 13 years, Ono Pharmaceutical Co's highest Return-on-Tangible-Equity was 18.17%. The lowest was 8.58%. And the median was 13.11%.
FRA:ON4's Return-on-Tangible-Equity is ranked better than 72.25% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs FRA:ON4: 16.08
Ono Pharmaceutical Co (FRA:ON4) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Ono Pharmaceutical Co Return-on-Tangible-Equity Related Terms
Ono Pharmaceutical Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Ono Pharmaceutical Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ono Pharmaceutical Co Return-on-Tangible-Equity Chart
FRA:ON4 vs LLY, JNJ, ABBV: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - General subindustry, Ono Pharmaceutical Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ono Pharmaceutical Co Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ono Pharmaceutical Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Ono Pharmaceutical Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.71% mean?
Ono Pharmaceutical Co (FRA:ON4) has a Return-on-Tangible-Equity of 0.71% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Ono Pharmaceutical Co and its competitors. This is 95% below median its historical median of 13.11. Over the past decade, Ono Pharmaceutical Co's Return-on-Tangible-Equity has ranged from 8.58 to 18.17. According to the industry distribution chart, Ono Pharmaceutical Co ranks #250 out of 901 companies in the Drug Manufacturers industry, placing it in the top 27.7%.
Is Ono Pharmaceutical Co's Return-on-Tangible-Equity too high?
Ono Pharmaceutical Co's current Return-on-Tangible-Equity of 0.71% is 95% below median its 10-year median of 13.11. Over the past 10 years, this metric has ranged from a low of 8.58 to a high of 18.17. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Ono Pharmaceutical Co's value of 0.71% is 91% below this industry median. Based on the distribution chart, Ono Pharmaceutical Co ranks #250 out of 901 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Ono Pharmaceutical Co has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ono Pharmaceutical Co's Return-on-Tangible-Equity compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Ono Pharmaceutical Co ranks #250 out of 901 companies for Return-on-Tangible-Equity. This puts Ono Pharmaceutical Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.90. Ono Pharmaceutical Co's value of 0.71% is 91% below this benchmark. Historically, Ono Pharmaceutical Co's own Return-on-Tangible-Equity has ranged from 8.58 to 18.17 over the past decade. While the company's 10-year median is 13.11 vs. the industry median of 7.90, Ono Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ono Pharmaceutical Co's current Return-on-Tangible-Equity of 0.71% is 91% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Ono Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ono Pharmaceutical Co's current Return-on-Tangible-Equity is 0.71%, which is 95% below median its own 10-year median of 13.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ono Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Ono Pharmaceutical Co (FRA:ON4) is currently considered Fairly Valued. The stock's GF Value™ is €12.10, compared to a current price of €12.90 — trading 6.6% above its estimated fair value. The current Return-on-Tangible-Equity is 0.71%, which is 95% below median its 10-year median of 13.11 and 91% below the Drug Manufacturers industry median of 7.90. Ono Pharmaceutical Co's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Ono Pharmaceutical Co (FRA:ON4), the current Return-on-Tangible-Equity is 0.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ono Pharmaceutical Co (FRA:ON4) Overvalued in 2026?
Based on GuruFocus' analysis, Ono Pharmaceutical Co stock appears to be overvalued.
The current stock price of €12.90 is trading 6.6% above its estimated GF Value™ of €12.10.
GuruFocus considers Ono Pharmaceutical Co to be Fairly Valued.
Key valuation signals for FRA:ON4:
Return-on-Tangible-Equity: 0.71% (95% below median its 10-year median of 13.11)
GF Value™: €12.10 vs. price of €12.90 (6.6% above fair value)
Industry Position: 91% below the Drug Manufacturers median (#250 of 901)
No single metric tells the full story. See the FRA:ON4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. The vast majority of the company's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of the company's sales is generated in Japan, followed by the rest of Asia and Europe.
87GF Score
Get the complete analysis for FRA:ON4
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ON4 has been successfully added to your 
